![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Aim
In January 2017, a new funding model for diagnostic genetic testing in cancer was introduced in Poland.
Objectives
The aim of this study was to assess the impact of changing the funding model for genetic diagnosis in oncology on improving access to personalized medicine in Poland between 2017 and 2019.
Methods
The analysis included data on settlements with the National Health Fund for genetic tests in cancer under a contract of the hospital treatment type and under the contract in the type of separately contracted services between 2017 and 2019.
Results
The 150,647 diagnostic genetic tests were reported, which were billed to 111,872 patients. The average number of tests per patient was 1.35. One test was billed to 83.5% of patients, 11.2% of patients had two tests billed, and 5.3% had at least three tests billed. The number of services provided under the hospital treatment contract in 2018 doubled compared to the previous year. For separately contracted services, more than threefold increase in genetic testing performed in 2019 compared to 2018 was observed.
Conclusion
our data show that the novel funding model for genetic services introduced in Poland has positive impact on the availability of genetic testing for patients.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
One peer reviewer declares: advisory board for BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV, Vial; consultant/Scientific Advisory Board (SAB) for Suba Therapeutics; research Support to institution from Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric; speaker and travel costs: BIO – INFORMAÇÃO BRASILEIRA DE ONCOLOGIA Ltda; Data safety monitoring committee honorarium: Mereo; spouse employed by Myriad; writing/editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence, MJH Life Sciences. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.
Author contributions
A Mela participated in the study design, methods quantitative analysis and interpretation of data. E Rdzanek participated in the study design, methods quantitative analysis and interpretation of data. A Tysarowski participated in the study design, methods, collection of the data, interpretation of data. M Sakowicz participated in the study design, methods, collection of the data, interpretation of data. J Jaroszyński participated in the study design, methods, interpretation of data. M Furtak-Niczyporuk participated in the study design, methods, interpretation of data. G Żurek participated in the interpretation of data. Ł Poniatowski participated in the interpretation of data. B Jagielska participated in the study design, methods, collection of the data, quantitative analysis and interpretation of data. All authors agree for the final version of the manuscript to be published.
Supplementary material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737167.2023.2140139